NBY (NovaBay Pharmaceuticals, Inc.) Stock Analysis - Analyst Ratings

NovaBay Pharmaceuticals, Inc. (NBY) is a publicly traded Healthcare sector company. As of May 21, 2026, NBY trades at $1.95 with a market cap of $51.92M and a P/E ratio of 0.12. NBY moved +23.42% today. Year to date, NBY is -62.14%; over the trailing twelve months it is -31.82%. Its 52-week range spans $1.11 to $99.75. Analyst consensus is hold with an average price target of $0.00. Rallies surfaces NBY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate NBY?

5 analysts cover NBY: 0 strong buy, 2 buy, 3 hold, 0 sell, and 0 strong sell. The consensus rating is hold. The average price target is $0.00.

NBY Key Metrics

Key financial metrics for NBY
MetricValue
Price$1.95
Market Cap$51.92M
P/E Ratio0.12
EPS$16.10
Dividend Yield0.80%
52-Week High$99.75
52-Week Low$1.11
Volume637.60K
Avg Volume0
Revenue (TTM)$2.46M
Net Income$522.59M
Gross Margin0.00%

NBY Analyst Consensus

5 analysts cover NBY: 0 strong buy, 2 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is hold. Average price target: $0.00.

Latest NBY News

Recent NBY Insider Trades

  • POPLAR POINT CAPITAL PARTNERS LP bought 300 (~$139.5) on Apr 8, 2025.
  • POPLAR POINT CAPITAL PARTNERS LP bought 4.54K (~$2.37K) on Apr 4, 2025.
  • POPLAR POINT CAPITAL PARTNERS LP bought 22.98K (~$12.93K) on Apr 3, 2025.

Common questions about NBY

What do analysts rate NBY?
5 analysts cover NBY: 0 strong buy, 2 buy, 3 hold, 0 sell, and 0 strong sell. The consensus rating is hold. The average price target is $0.00.
Does Rallies show NBY price targets?
Yes. Rallies tracks NBY analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is NBY research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NBY. It does not provide personalized investment advice.
NBY

NBY